KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Income from Non-Controlling Interests (2019 - 2025)

Historic Income from Non-Controlling Interests for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $141.7 million.

  • Royalty Pharma's Income from Non-Controlling Interests rose 1234.45% to $141.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $553.2 million, marking a year-over-year increase of 1725.52%. This contributed to the annual value of $553.2 million for FY2025, which is 1725.52% up from last year.
  • As of Q4 2025, Royalty Pharma's Income from Non-Controlling Interests stood at $141.7 million, which was up 1234.45% from $156.0 million recorded in Q3 2025.
  • Royalty Pharma's Income from Non-Controlling Interests' 5-year high stood at $366.0 million during Q2 2021, with a 5-year trough of -$153.9 million in Q4 2022.
  • Over the past 5 years, Royalty Pharma's median Income from Non-Controlling Interests value was $121.8 million (recorded in 2021), while the average stood at $120.0 million.
  • As far as peak fluctuations go, Royalty Pharma's Income from Non-Controlling Interests plummeted by 43636.9% in 2022, and later surged by 225538.61% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Income from Non-Controlling Interests stood at $45.8 million in 2021, then plummeted by 436.37% to -$153.9 million in 2022, then surged by 245.02% to $223.2 million in 2023, then plummeted by 43.5% to $126.1 million in 2024, then grew by 12.34% to $141.7 million in 2025.
  • Its last three reported values are $141.7 million in Q4 2025, $156.0 million for Q3 2025, and $60.5 million during Q2 2025.